Results from the ABIGAIL study presented at ESMO24

ESMO – European Society for Medical Oncology shared a post on LinkedIn:

“At ESMO24 results from the ABIGAIL study showed that the CDK 4/6 inhibitor abemaciclib combined with endocrine therapy (ET) achieved a higher early overall response rate at 12 weeks compared to standard chemotherapy as first-line treatment in patients with hormone receptor-positive (HR+)/HER2-negative advanced Breast Cancer with aggressive disease characteristics.

Read the full news on the ESMO Daily Reporter.”

Source: ESMO/LinkedIn

More posts featuring ESMO on oncodaily.com

The European Society for Medical Oncology (ESMO) represents over 35,000 oncology professionals across 172 countries and is a key resource for oncology education and information. ESMO’s primary mission is to enhance the quality of cancer care, spanning prevention, diagnosis, palliative care, and patient follow-up.

It focuses on educating doctors, cancer patients, and the general public about best practices and the latest advancements in oncology, and advocates for equal access to optimal cancer care for all patients.